Pancreatic Cancer Research

ResearcherTufts UniversityNo recent work listed

Frank Charles Passero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7428-8826; OpenAlex author ID A5064711111. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper

Papers 4

  1. Second line treatment options for pancreatic cancer. Co-author DOI 10.1080/14656566.2017.1369955↗
  2. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Co-author DOI 10.1080/14737140.2016.1192471↗
  3. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Co-author DOI 10.1177/1756283x15622601↗
  4. Advancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015). Co-author DOI 10.6092/1590-8577/2955↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Muhammad Wasif Saif · 4 shared papers, 2015–2017 · strength 0.40
  2. Dimitra Grapsa · 1 shared paper, 2016 · strength 0.08
  3. Kostas Syrigos · 1 shared paper, 2016 · strength 0.08
  4. Matthew J. Abrams · 1 shared paper, 2016 · strength 0.07
  5. Yuxia Jia · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.